Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response

Peptides

Volumn 27, Issue 7, 2006, Pages 1776-1786

  Boriani, Giuseppe ^a   Regoli, François ^b   Saporito, Davide ^a   Martignani, Cristian ^a   Toselli, Tiziano ^b   Biffi, Mauro ^a   Francolini, Gloria ^c   Diemberger, Igor ^a   Bacchi, Letizia ^a   Rapezzi, Claudio ^a   Ferrari, Roberto ^b,c   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c IRCCS   (Italy)

Author keywords

Cardiac resynchronization therapy; Cytokines; Heart failure; Natriuretic peptides; Neurohormones; Sudden death

Indexed keywords

ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CHROMOGRANIN A; INTERLEUKIN 6; NEUROHORMONE; NORADRENALIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; CARDIAC PACING, ARTIFICIAL; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745113581     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.02.010     Document Type: Article

References (53)

1. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997;35:2-3.
2. Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., Kocovic D.Z., Packer M., Clavell A.L., Hayes D.L., Ellestad M., Trupp R.J., Underwood J., Pickering F., Truex C., McAtee P., and Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
3. Agnoletti L., Curello S., Bachetti T., Malacarne F., Gaia G., Comini L., Volterrani M., Bonetti P., Parrinello G., Cadei M., Grigolato P., and Ferrari R. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 100 (1999) 1983-1991
4. Apple F.S., Panteghini M., Ravkilde J., Mair J., Wu A., Tate J., Pagani F., Christenson R.H., Jaffe A.S., and IFCC CoSoMoCDot. Quality specifications for B-type natriuretic peptide assays. Clin Chem 51 (2005) 486-493
5. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
6. Blanc J.J., Etienne Y., Gilard M., Mansourati J., Munier S., Boschat J., Benditt D.G., and Lurie K.G. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation 96 (1997) 3273-3277
7. Boriani G., Biffi M., Martignani C., Fallani F., Greco C., Grigioni F., Corazza I., Bartolini P., Rapezzi C., Zannoli R., and Branzi A. Cardiac resynchronization by pacing: an electrical treatment of heart failure. Int J Cardiol 94 (2004) 151-161
8. Boriani G, Diembergr I, Biffi M, Martignani C, Valzania C, Ziacchi M, Bertini M, Specchia S, Grigioni F, Rapezzi C and Branzi A. Cardiac resynchronization therapy in clinical practice: need for electrical, mechanical, clinical and logistic synchronization. Pacing Clin Electrophysiol; in press.
9. Boriani G., Fallani F., Martignani C., Biffi M., Saporito D., Greco C., Ziacchi M., Levorato M., Pontone G., Valzania C., Diemberger I., Franchi R., and Branzi A. Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. Pacing Clin Electrophysiol 28 Suppl 1 (2005) S11-S14
10. Braun M.U., Rauwolf T., Zerm T., Schulze M., Schnabel A., and Strasser R.H. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart 91 (2005) 601-605
11. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W., and Feldman A.M. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
12. Cazeau S., Leclercq C., Lavergne T., Walker S., Varma C., Linde C., Garrigue S., Kappenberger L., Haywood G.A., Santini M., Bailleul C., and Daubert J.C. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
13. Ceconi C., Condorelli E., Quinzanini M., Rodella A., Ferrari R., and Harris P. Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. Cardiovasc Res 23 (1989) 674-682
14. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., and Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23 (2002) 967-974
15. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., and Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
16. Clerico A., and Emdin M. Endocrine paradox in heart failure: resistance to biological effects of cardiac natriuretic hormones. Clin Chem 50 (2004) 2465-2467
17. Clerico A., Prontera C., Emdin M., Passino C., Storti S., Poletti R., Zyw L., and Zucchelli G. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 51 (2005) 445-447
18. De Tommasi E., Iacoviello M., Romito R., Ceconi C., Guida P., Massari F., Francolini G., Bertocchi F., Ferrari R., Rizzon P., and Pitzalis M. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 146 (2003) E17
19. Doust J., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625
20. Fedak P.W., Verma S., Weisel R.D., and Li R.K. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 14 (2005) 1-11
21. Ferrari R. Interleukin-6: a neurohumoral predictor of prognosis in patients with heart failure: light and shadow. Eur Heart J 23 (2002) 9-10
22. Ferrari R., Bachetti T., Confortini R., Opasich C., Febo O., Corti A., Cassani G., and Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
23. Ferrari R., Ceconi C., Curello S., and Visioli O. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J 19 Suppl F (1998) F45-F51
24. Francis G.S. Pathophysiology of chronic heart failure. Am J Med 110 Suppl 7A (2001) 37S-46S
25. Gregoratos G., Abrams J., Epstein A.E., Freedman R.A., Hayes D.L., Hlatky M.A., Kerber R.E., Naccarelli G.V., Schoenfeld M.H., Silka M.J., Winters S.L., Gibbons R.J., Antman E.M., Alpert J.S., Hiratzka L.F., Faxon D.P., Jacobs A.K., Fuster V., and Smith Jr. S.C. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 (2002) 2145-2161
26. Higgins S.L., Yong P., Sheck D., McDaniel M., Bollinger F., Vadecha M., Desai S., and Meyer D.B. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. J Am Coll Cardiol 36 (2000) 824-827
27. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldmanmd A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., Noble R.J., Packer M., Silver M.A., Stevenson L.W., Gibbons R.J., Antman E.M., Alpert J.S., Faxon D.P., Fuster V., Jacobs A.K., Hiratzka L.F., Russell R.O., and Smith Jr. S.C. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104 (2001) 2996-3007
28. Levine B., Kalman J., Mayer L., Fillit H., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
29. Mann D., and Young J. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105 (1994) 897-904
30. McAlister F.A., Ezekowitz J.A., Wiebe N., Rowe B., Spooner C., Crumley E., Hartling L., Klassen T., and Abraham W. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 141 (2004) 381-390
31. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., Tunstall-Pedoe H., McMurray J.J., and Dargie H.J. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
32. Miller W.L., Bailey K.R., Weston S.A., Burnett Jr. J.C., and Rodeheffer R.J. Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function. Eur J Heart Fail 4 (2002) 63-72
33. Moe G.W., Grima E.A., Wong N.L., Howard R.J., and Armstrong P.W. Dual natriuretic peptide system in experimental heart failure. J Am Coll Cardiol 22 (1993) 891-898
34. Moe G.W., Grima E.A., Wong N.L., Howard R.J., and Armstrong P.W. Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. J Am Coll Cardiol 27 (1996) 720-727
35. Molhoek S.G., Bax J.J., van Erven L., Bootsma M., Steendijk P., Lentjes E., Boersma E., van der Laarse A., van der Wall E.E., and Schalij M.J. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 90 (2004) 97-98
36. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 71 (1993) 3C-11C
37. Pitzalis M.V., Iacoviello M., Romito R., Massari F., Rizzon B., Luzzi G., Guida P., Andriani A., Mastropasqua F., and Rizzon P. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol 40 (2002) 1615-1622
38. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., and Yandle T.G. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99 (1999) 786-792
39. Rodeheffer R.J. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?. J Am Coll Cardiol 44 (2004) 740-749
40. Saxon L.A., De Marco T., Schafer J., Chatterjee K., Kumar U.N., and Foster E. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 105 (2002) 1304-1310
41. Saxon L.A., and Ellenbogen K.A. Resynchronization therapy for the treatment of heart failure. Circulation 108 (2003) 1044-1048
42. Sinha A.M., Filzmaier K., Breithardt O.A., Kunz D., Graf J., Markus K.U., Hanrath P., and Stellbrink C. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 91 (2003) 755-758
43. Smedes F., Kraak J., and Poppe H. Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine. J Chromatogr 231 (1982) 25-39
44. St John Sutton M.G., Plappert T., Abraham W.T., Smith A.L., DeLurgio D.B., Leon A.R., Loh E., Kocovic D.Z., Fisher W.G., Ellestad M., Messenger J., Kruger K., Hilpisch K.E., and Hill M.R. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107 (2003) 1985-1990
45. Strickberger S.A., Conti J., Daoud E.G., Havranek E., Mehra M.R., Pina I.L., and Young J. Patient selection for cardiac resynchronization therapy: from the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 111 (2005) 2146-2150
46. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
47. Valgimigli M., Agnoletti L., Curello S., Comini L., Francolini G., Mastrorilli F., Merli E., Pirani R., Guardigli G., Grigolato P., and Ferrari R. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. Circulation 107 (2003) 264-270
48. Valgimigli M., Ceconi C., Malagutti P., Merli E., Soukhomovskaia O., Francolini G., Cicchitelli G., Olivares A., Parrinello G., Percoco G., Guardigli G., Mele D., Pirani R., and Ferrari R. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 111 (2005) 863-870
49. Valgimigli M., Rigolin G., Fucili A., Porta M., Soukhomovskaia O., Malagutti P., Bugli A., Bragotti L., Francolini G., Mauro E., Castoldi G., and Ferrari R. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110 (2004) 1209-1212
50. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., Wolf P.A., and Vasan R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
51. Wu A.H., and Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6 (2004) 355-358
52. Wu A.H., Smith A., Wieczorek S., Mather J.F., Duncan B., White C.M., McGill C., Katten D., and Heller G. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
53. Yan R.T., White M., Yan A.T., Yusuf S., Rouleau J.L., Maggioni A.P., Hall C., Latini R., Afzal R., Floras J., Masson S., and McKelvie R.S. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96 (2005) 698-704